Mouse chromosome 17 candidate modifier genes for thrombosis
- First Online:
- Cite this article as:
- Sa, Q., Hart, E., Nadeau, J.H. et al. Mamm Genome (2010) 21: 337. doi:10.1007/s00335-010-9274-6
- 352 Downloads
Two overlapping quantitative trait loci (QTLs) for clot stability, Hmtb8 and Hmtb9, were identified on mouse chromosome 17 in an F2 intercross derived from C57BL/6J (B6) and B6-Chr17A/J (B6-Chr17) mouse strains. The intervals were in synteny with a QTL for thrombotic susceptibility on chromosome 18 in a human study, and there were 23 homologs between mouse and human. The objective of this study was to determine whether any of these genes in the syntenic region are likely candidates as modifiers for clot stability. Seven genes, Twsg1, Zfp161, Dlgap1, Ralbp1, Myom1, Rab31, and Emilin2, of the 23 genes with single nucleotide polymorphisms (SNPs) in the mRNA-UTR had differential expression in B6 and A/J mice. Dlgap1, Ralbp1, Myom1, and Emilin2 also had nonsynonymous SNPs. In addition, two other genes had nonsynonymous SNPs, Lama1 and Ndc80. Of these nine candidate genes, Emilin2 was selected for further analysis since other EMILIN (Elastin Microfibril Interface Located Protein) proteins have known functions in vascular structure and coagulation. Differences were found between B6 and A/J mice in vessel wall architecture and EMILIN2 protein in plasma, carotid vessel wall, and thrombi formed after ferric chloride injury. In B6-Chr17A/J mice both clot stability and Emilin2 mRNA expression were higher compared to those in B6 and A/J mice, suggesting the exposure of epistatic interactions. Although other homologous genes in the QTL region cannot be ruled out as causative genes, further investigation of Emilin2 as a candidate gene for thrombosis susceptibility is warranted.
Thrombosis occurs as a consequence of vascular injury due to an imbalance between the pathways that regulate thrombus formation and/or dissolution and is the major fatal event of cardiovascular diseases (Voetsch and Loscalzo 2004). Great strides have been made in the diagnosis and treatment of thrombosis in the last decade. However, strategies to prevent thrombosis have lagged far behind partly because of the contribution of multiple and as yet undefined genetic factors that lead to thrombotic risk. Moreover, it remains unclear how genetic background influences the function of molecules and pathways known to regulate thrombus formation and lysis, thereby contributing to the risk of thrombotic disease (Ginsburg 2005).
To investigate genetic differences in thrombosis, we identified two inbred mouse strains, B6 and A/J, that have marked differences in a tail bleeding/rebleeding assay and response to FeCl3-induced carotid injury (Hoover-Plow et al. 2006). In the tail bleeding/rebleeding assay, an established hemostasis and thrombosis reporter assay, there was no difference in the first bleeding time between the B6 and the A/J mice. Interestingly, the time for the second bleeding to occur was increased in A/J mice compared to B6 mice by nearly threefold, indicating enhanced clot stability (Hoover-Plow et al. 2006) in the A/J mice. A marked difference of twofold in arterial thrombus occlusion time was found between the B6 and the A/J mice in the FeCl3 carotid artery injury model.
Surveying a panel of 21 chromosome substitution strains (CSS) in which individual A/J chromosomes were replaced in a B6 background, three chromosomes were identified with modifier genes for clot stability (Hoover-Plow et al. 2006): Hmtb1 (chromosome 5), Hmtb2, (chromosome 11), and Hmtb3 (chromosome 17). Quantitative trait locus (QTL) analysis was performed in F2 mice (B6 × B6-Chr5, B6-Chr11, and B6-Chr17 strains) and QTL mapping led to identification of a significant locus on chromosome 5 (Hmtb4), a suggestive locus on chromosome 11 (Hmtb5), and two suggestive overlapping QTLs on mouse chromosome 17 (Hmtb8, 9). The mouse QTL intervals on chromosome 17 are in synteny with a previously identified QTL for thrombosis risk on human chromosome 18 (Soria et al. 2003). The syntenic region contains 23 homologous genes and the purpose of this study was to determine whether any of these genes in the syntenic region are likely candidates as modifiers for clot stability.
Differential expression in B6 and A/J mice in seven of the homologous genes with SNPs in the regulatory regions was confirmed. One of the genes expressed in the cardiovascular system, Emilin2, was differentially expressed in lung of B6, A/J, and B6-Chr17 mice and in liver and bone marrow of B6 and A/J mice. Sequence analysis of Emilin2 identified novel SNPs in the coding and promoter regions between B6 and A/J that could alter expression and/or protein–protein interactions. In B6-Chr17 mice clot stability and Emilin2 expression was higher than in A/J mice, suggesting that there is a modifier gene from another chromosome. EMILIN2 protein was found in platelets, aorta, macrophages, plasma, vessel wall, and thrombi. EMILIN2 may regulate thrombosis by maintaining vessel architecture and/or clot lysis susceptibility. Our data support further investigation of Emilin2 as a promising candidate modifier gene for thrombosis risk.
The inbred strains B6 (#000664) and A/J (#000646) were obtained from the Jackson Laboratory (Bar Harbor, ME) at 6 weeks of age. B6-Chr17 mice with A/J chromosome 17 in a B6 background, previously described (Nadeau et al. 2000; Singer et al. 2004), were provided by Dr. Nadeau or by Jackson Laboratory (#004395) and housed and bred at the Biological Resource Unit at the Cleveland Clinic Lerner Research Institute. Experiments were carried out on mice between 7 and 9 weeks of age. All animal experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee at the Cleveland Clinic.
RT-PCR and real-time PCR
Total RNA was purified from the tissues and the cells of A/J and B6 mice using the RNeasy Mini Kit (Qiagen, Valencia, CA), treated with TURBO DNase (Ambion, Austin, TX), and reverse transcribed into cDNA using SuperScriptTM III First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) according to the manufacturers’ instructions. RT-PCR was performed using 50 ng of cDNA from A/J and B6 mice as templates. The PCR product was analyzed on 1 or 1.2% agarose gel and recovered using the QIAquick Gel Extraction Kit (Qiagen). Sequencing (ABI 3730xl, Applied Biosystems, Foster City, CA) was performed at the Genomic Core of Cleveland Clinic. Negative controls that cannot undergo reverse transcription were included in the cDNA synthesis step. Real-time PCR was performed using an iCycler iQ (Bio-Rad Laboratories, Hercules, CA). Each amplification reaction contained 20 ng of cDNA, 300 nM of each primer, 25 μl of 2 × power SYBR® Green Master Mix (Applied Biosystems, Warrington, UK), and 0.5 μl of UNG (Applied Biosystems) added to prevent carryovers. Samples were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Operon, Huntsville, AL). The comparative cycle threshold method was used to analyze the data. RNA was isolated from five to six mice for each group and analyzed in triplicate. All the primers are listed in Supplementary Table 1.
PCR for cloning promoters and noncoding regions
Genomic DNA was isolated from hearts of A/J and B6 mice using a DNA Mini Kit (Qiagen). In order to minimize errors, Expand High Fidelity PCR system (Roche, Indianapolis, IN) was used for PCR. The 25-μl reaction system contained 100 ng of DNA template and 200 nM of each primer (listed in Supplementary Table 1). The estimated error with this method is approximately 3/105 bp. As above, the PCR product was analyzed on agarose gel, recovered, and sequenced by the Genomic Core at the Cleveland Clinic. The cloning and sequencing was repeated twice and the same sequencing results were found.
Generation of EMILIN2 anti-peptide antibody
A polyclonal antibody (E185) for mouse EMILIN2 was generated in rabbits. Since EMILIN2 has a high homology to EMILIN1, a peptide was synthesized from residues 829–843 located in the proline-rich domain specific to EMILIN2. To increase the specificity of the antibody, the rabbit antiserum was subjected to affinity purification using the peptide. To test the specificity of the antibody, HEK293 cells were transfected with the construct E2-N1 that contains EMILIN2-EGFP fusion gene and construct PR-N1 that harbors the PR domain–EGFP fusion gene. The vector N1 that contains only the EGFP gene was used as negative control. Constructs containing EMILIN2 protein domains, namely, Collagen-like C1q domains that do not interact with the antibody, and EGFP fusion genes, were also used as negative controls. Using the purified antibody, Western blot detected a single band at approximately 150 kDa, which is the predicted molecular weight for the EMILIN2-EGFP fusion protein from the E2-N1 construct and approximately 50-kDa band for the PR-EGFP fusion protein. In contrast, no band was detected from the cells transfected with vector alone or the Col-EGFP and C1q-EGFP constructs. Using an antibody against EGFP, the same 150-kDa single band was detected from cells transfected with E2-N1 and a 50-kDa band was detected for PR-EGFP. On the other hand, only one band around 30 kDa (EGFP) was detected from cells transfected with N1 vector. The EGFP antibody also detected the domain-EGFP fusion proteins with the predicted molecular weight for each construct; this indicates that E185 binds specifically to the PR region of EMILIN2.
The mice were perfused with PBS and aortas were harvested, homogenized, and lysed in RIPA buffer (R0278, Sigma, St. Louis, MO) with protease inhibitors (P8340, Sigma). Platelets were gel filtration purified and lysed with RIPA buffer with protease inhibitors. Plasma was collected by centrifuging citrated blood at 1000 g for 10 min and mixed with 2 × Laemmli sample buffer (Bio-Rad). Peritoneal lavage was collected 72 h after treatment, with 0.5 ml of 4% thioglycollate and peritoneal macrophages were harvested, washed with PBS, and suspended in RIPA buffer. About 95% of the cells were macrophages, identified by Wright’s staining, and the viability was greater than 95%, as assessed by trypan blue staining. Protein concentration was measured with the Protein Assay (Bio-Rad). For Western blots, 10 μg of protein was loaded in each lane for SDS-PAGE gels, which were transferred to PVDF membranes. The membranes were incubated with rabbit anti-EMILIN2 (E185), goat anti-EMILIN2 (Q-16, sc-51356, Santa Cruz Biotechnology, Santa Cruz, CA) and EMILIN1 (sc-27569, Y-13, Santa Cruz) antibodies, and HRP-conjugated anti-rabbit or anti-goat secondary antibodies. Protein bands were detected using the ECL detection system (GE Healthcare, Buckinghamshire, UK). A protein loading control, β-actin, was detected with antibody (A5441, Sigma).
FeCl3 carotid injury and immunohistochemical staining
To induce thrombus formation in the carotid artery, a ferric chloride (FeCl3) model of vessel injury was employed as previously described (Hoover-Plow et al. 2006). The flow probe (model 0.5PSB, Transonic Systems, Ithaca, NY) was in place from baseline measurements to several minutes after the stable occlusion had been reached or stopped at 30 min if it had not occluded. Blood flow was recorded every 10 s (model TS420, Transonic Systems). After cardiac perfusion, the carotid arteries were harvested after occlusion, immediately embedded into OCT (Tissue-Tek, Torrance, CA), and frozen. The frozen carotid arteries were sectioned at 10 μm using a cryostat (Leica CM1850, Leica Microsystems, Nassloch, Germany), fixed with acetone at 4°C for 10 min, then blocked with normal serum. EMILIN2 was detected with E185 or Q-16 antibodies and P-selectin with rabbit anti-CD62P antibody (BD Biosciences, San Diego, CA). The sections were then incubated with 1:1000 diluted biotinylated appropriate secondary antibodies (PK-6101, PK-6105 Vectastain ABC Kit, Vector Laboratories, Burlingame, CA), and proteins were visualized with alkaline phosphatase substrate. For quantification analysis, six sections of each carotid and six mice from each group were measured and analyzed using Image-Pro Plus (Media Cybernetics, Silver Spring, MD).
Values are presented as mean ± SEM. Statistical differences were assayed by a t test or ANOVA with Newman-Keuls post-test.
Clot stability is enhanced in A/J and B6-Chr17 mice compared to B6 mice
Patency in B6, A/J, and B6-Chr17 mice in FeC13-induced vascular injury
Mean blood flow (ml/min)
0.48 ± 0.08
0.47 ± 0.07
0.05 ± 0.01
0.04 ± 0.01
0.22 ± 0.06
0.16 ± 0.02
0.06 ± 0.01
0.45 ± 0.08*
0.31 ± 0.08**
0.05 ± 0.01
Expression of homologous genes
Expression analysis of the homologous genes in the syntenic QTL interval by real-time PCR
VAMP-associated protein A
Thioredoxin domain containing 2
Member RAS oncogene family
Protein phosphatase, regulatory subunit 1
ralA binding protein 1
Twisted gastrulation homolog 1 (drosophila)
Ankyrin repeat domain 12
NADH dehydrogenase flavoprotein 2
RAB12, member RAS oncogene family
Protein tyrosine phosphatase receptor M
Leucine-rich repeat containing 30
Laminin, alpha 1
Rho GTPase activating protein 28
Erythrocyte protein band 4.1-like 3
Zinc finger protein 161
Large (drosophila) homolog-associated protein 1
TG interacting factor
Myosin light chain 12 B regulatory
Elastin microfibril interfacer 2
SMC hinge domain containing 1
Kinetochore complex component
SNPs in the homologous genes
Mouse genes on Chr 17 homologous to genes in human QTL on Chr 18
Six genes, Ralbp1, Lama1, Dlgap1, Myom1, Emilin2, and Ndc80, had nonsynonymous SNPs in the coding region. Twelve genes, Rab31, Ppp4r1, Ralbp1, Twsg1, Zfp161, Dlgap1,Tgif, Myom1, Lpin2, Emilin2, Smchd1, and Ndc80, had SNPs in the mRNA-UTR. Eleven genes had SNPs in the 2-kb noncoding regions: Ppp4r1, Ralbp1, Lrrc30, Epb4.1l3, Zfp161, Tgif, Myl12b, Myom1, Lpin2, Emilin2, and Smchd1. Although not determined in this study, regions outside the 2-kb region could also alter the expression of genes. Thus, 16 of the 23 homologous genes had SNPs in the coding region or mRNA-UTR and could be candidate genes. Four of these genes, Twsg1, Zfp161, Dlgap1, and Emilin2, with SNPs in the mRNA-UTR, also had differential expression in liver of B6 and A/J mice, suggesting that these four genes have great potential to be candidate genes. In addition, Ralbp1, Myom1, and Rab31 were reported to be differentially expressed in lung or heart (Microarray data, C. N. Henrichsen et al., Record GSE10744, released in 2009 from Gene Express Omnibus). Thus, for 7 of the 16 genes with SNPs in the regulatory regions, differential expression was confirmed. Two genes, Lama1 and Ndc80, had nonsynonymous SNPs. These nine genes (7 with SNPs in regulatory regions and differential expression plus 2 genes with nonsynonymous SNPs) were considered to be candidate genes and their known functions and distribution were evaluated.
Of the known functions and distribution of the genes and gene products identified above with SNPs in the mRNA-UTR and/or nonsynonymous SNPs, Emilin2 seemed the most likely candidate gene. Because EMILIN2 and other EMILIN proteins are associated with the cardiovascular system (Christian et al. 2001; Hayward et al. 1993, 2004; Lembertas et al. 1997; Milanetto et al. 2008), we selected Emilin2 for further analysis. In addition to differential expression in B6 and A/J mice, Emilin2 had nonsynonymous SNPs in the coding region and SNPs in the potential regulatory regions, based on the MGI and Sanger databases. Because Emilin2 could be a causative gene in this QTL, examination of the expression and polymorphisms was undertaken with B6, A/J, or B6-Chr17 mouse strains.
Expression of Emilin2 in lung, bone marrow cells, heart, and aorta
EMILIN2 expression by quantitative real-time PCR in tissue
Fold change of A/J from B6
Fold change from liver B6
Fold change from liver A/J
0.50 ± 0.05
0.79 ± 0.06
1.50 ± 0.65
6.45 ± 1.42
1.93 ± 0.32
1.08 ± 0.17
2.60 ± 0.49
3.44 ± 0.96
32.5 ± 8.06
65.2 ± 10.58
Since Doliana et al. (2001) demonstrated a robust expression of Emilin2 mRNA in peripheral leukocytes, bone marrow cells were tested for Emilin2 mRNA expression. Emilin2 expression was twofold higher (P = 0.04) in bone marrow cells from A/J than from B6 mice (Table 4). In addition, the expression level of Emilin2 was over tenfold higher in bone marrow cells than in other tissues from the same strain. Bone marrow has hematopoietic cells, including red cells and platelets important for blood clotting. Differences in expression of Emilin2 in tissue and bone marrow between B6, A/J, and B6-Chr17 along with prolonged clot stability in B6-Chr17 suggest that Emilin2 may be a candidate gene for thrombosis susceptibility.
Nucleotide polymorphisms in Emilin2
Polymorphisms in Emilin2 between A/J and B6
Amino acid polymorphisms
SNPs in promoter
SNPs in 5′-noncoding region
To determine whether there are nucleotide polymorphisms in the upstream and noncoding regions in Emilin2, the 1.5-kb upstream region and the 5′- and 3′-noncoding mRNA regions were cloned from A/J or B6 mouse strains (Table 5). No polymorphisms were detected in the 3′-noncoding mRNA region. In the 5′-noncoding region, single nucleotide deletions were found in A/J and B6 at two locations (Table 5). A total of eight SNPs were detected in the 1.5-kb putative promoter region, including two substitutions in the proximal region and two substitutions and four deletions (in B6) in the distal region. These SNPs in the promoter and 5′-noncoding region may explain the differential expression of Emilin2 in certain tissues.
Function of Emilin2 in thrombosis
Extracellular matrix in vessels of B6 and A/J mice
Artery collagen (%)
33 ± 5 (10)
48 ± 3** (11)
Vein collagen (%)
47 ± 6 (6)
57 ± 4 (11)
Tail collagen (%)
33 ± 4 (5)
42 ± 4* (4)
Carotid injury (ratio injured to uninjured)
Internal elastic lamina
1.48 ± 0.02 (6)
1.05 ± 0.07** (6)
External elastic lamina
1.36 ± 0.03 (6)
0.96 ± 0.05** (6)
The prolonged clot stability in the bleeding/rebleeding assay identified previously in B6-Chr17 mice was confirmed in a direct thrombotic assay of FeCl3-induced carotid injury. In B6 mice only 10% of the carotids remained occluded at 24 h, while in the B6-Chr17 mice 100% remained occluded. Expression analysis of the 23 homologous genes in the syntenic region of QTLs for thrombosis risk in mice and humans revealed 7 genes that had SNPs in the regulatory regions and altered expression in tissues: Rab31, Ralbp1, Twsg1, Zfp161, Dlgap1, Myom1, and Emilin2. Two other genes had nonsynonymous SNPs without increased expression, Lama1 and Ndc80. These nine genes are the most likely candidate genes. EMILIN2 is a member of the EMILIN proteins found in the cardiovascular system and was selected for further analysis. This study found high mRNA expression of Emilin2 in bone marrow compared to other tissues. Sequencing of Emilin2 in B6 or A/J mice identified SNPs in both coding and potential regulatory regions. In addition, EMILIN2 protein differential expression was identified in plasma, the vessel wall, and thrombi, suggesting a potential direct role in clot stability. Furthermore, EMILIN2 in the vessel wall and altered composition and architecture in B6 and A/J vessel walls implicates a second potential role of EMILIN2 in the response to vascular injury.
The two QTLs Hmtb8 and Hmtb9, which regulate clot stability, were previously identified on mouse Chr 17 (Sa et al. 2008). These two loci map to a syntenic region that contains a QTL controlling thrombosis susceptibility in humans (Soria et al. 2003). There are several genetic differences that can cause variation in the expression of a gene: (1) Genes have nonsynonymous SNPs that change amino acids in the coding region, (2) genes have SNPs in the regulatory regions, or (3) the gene products differ in their expression levels (Glazier and Nadeau 2002; Wang et al. 2005). In addition to identification of splice variants (Marcucci and Romano 2008; Zavolan and van Nimwegen 2006), recent studies have suggested that copy number variability (Cutler et al. 2007; Graubert et al. 2007; Henrichsen et al. 2009; She et al. 2008) and microRNA regulation (Prasad et al. 2009) can cause differences in gene and gene product expression. This study focused on the identification of SNPs in the homologous genes between B6 and A/J mice.
There were two genes that had nonsynonymous SNPs: Lama1 and Ndc80. Lama1 is a basement membrane component and is limited primarily to epithelium in both embryonic development and in adults (Ekblom et al. 2003). Lama1 deficiency in mice is embryonically lethal (Alpy et al. 2005). Ndc80 is involved in the interface between centromeres and spindle microtubules, and it’s overexpression is associated with tumors (Diaz-Rodriguez et al. 2008). Seven genes that contained SNPs were identified in mRNA-UTR and had confirmed differential expression in B6 and A/J mice: Twsg1, Zfp161, Dlgap1, Ralbp1, Myom1, Rab31, and Emilin2. Mammalian Tswg1 is associated with salivary gland epithelial development. Twsg1-deficient mice have craniofacial and skeletal structure defects and more than half of the deficient mice exhibit dwarfism and fail to thrive (MacKenzie et al. 2009; Melnick et al. 2006). Zfp161 is expressed in neural tissue, is involved in transcription regulation (Numoto et al. 1993), and is linked to a gene associated with an inheritable developmental disorder, holoprosencephaly (Sobek-Klocke et al. 1997). Dlgap1 is expressed in the brain and neural tissues and functions in synaptic transmission and cell-cell signaling (Bouwman et al. 2006; Nguyen et al. 2005). Ralbp1 has GTPase activity, and homozygous and heterozygous mice have increased sensitivity to irradiation, oxidative stress, and impaired glutathione homeostasis (Singhal et al. 2008). Myom1 is a structural constituent of cytoskeleton and is involved in muscle contraction (Price and Gomer 1993; Steiner et al. 1999). Rab31 participates in Golgi vesicle transport and GTP binding (Rodriguez-Gabin et al. 2009). It is not apparent that these eight genes discussed above could be causative genes for thrombosis modifiers.
Of the nine candidate genes, Emilin2 seems to be the most likely candidate for the causative gene for thrombosis. EMILIN2 is one of the EMILIN (Elastin Microfibril Interface Located Protein) proteins, which are a group of extracellular matrix glycoproteins (Colombatti et al. 2000). This family comprises at least four proteins, including EMILIN1, EMILIN2, Multimerin1, and Multimerin2, with the major site of expression in the cardiovascular system, including the vascular wall and platelets (Christian et al. 2001; Hayward et al. 1993; Zacchigna et al. 2006). EMILIN1 deficiency causes disruptions of the endothelial cell layer and interruptions of the elastic lamellae of large vessels (Zanetti et al. 2004). Other extracellular proteins, including elastin (Milewicz et al. 2000), fibulins (Argraves et al. 2003), fibrillar proteins (Robinson and Godfrey 2000), thrombospondins (Stenina et al. 2007), and collagens (Gould et al. 2005; Malfait et al. 2006), important for vascular wall architecture, are required for recovery from injury and prevention of vascular disease. In addition, ECM proteins, including fibulin1 (Argraves et al. 2003), thrombospondins (Stenina et al. 2007), and collagen (Gould et al. 2005; Malfait et al. 2006), are found in plasma and have been used as biomarkers for cardiovascular disease.
In this study we report that EMILIN2 may function in two ways to regulate thrombosis: (1) as a component of the vascular wall and critical for maintaining the vessel architecture and response to injury, and (2) as a component of the thrombus facilitating clot lysis. A recent study reports downregulation of EMILIN2 in brain arteriovenous malformations (Sasahara et al. 2007). Furthermore, a number of proteomic and microarray studies of human tissues have identified EMILIN2 in extracellular fluids (plasma, amniotic, seminal, and synovial), stem cells (hematopoietic, mesenchymal, and osteoblasts), stimulated endometrial stromal cells, and cancer cells (lymphocytic leukemia, hepatic, colorectal, and ovarian cancer). In addition, microarray data (T. C. Somervaille et al., Record GSE13693) released in 2009 from GEO analyzed gene expression in bone marrow cell populations in B6 mice. Analysis of the data revealed that EMILIN2 was significantly increased in mature neutrophils compared to undifferentiated hematopoietic cells (3.6-38-fold, P < 0.001). These studies suggest that EMILIN2 plays important physiological and pathological roles. The identification of EMILIN2 in plasma in humans as well as in mice supports the hypothesis that EMILIN2 could play a role in thrombosis.
Emilin2 mRNA expression has been reported in spleen and uterus (Braghetta et al. 2004); fetal heart, lung, placenta, and peripheral leukocytes (Doliana et al. 2001); cochlear basement membrane (Amma et al. 2003); and optic tissues (Scavello et al. 2005). Emilin2 is expressed in the vasculature and heart in zebrafish during embryonic development and in adults (Milanetto et al. 2008). In this study, both nonsynonymous SNPs and expression differences for Emilin2 were observed in A/J and B6 mice. Furthermore, the amino acid changes are the same in A/J mice and in another strain, 129/svJ (see Supplementary Fig. 2 and Table 2), which also has prolonged clot stability. For the QTLs on chromosome 17, from 66 to 66.6 Mb in the syntenic region, 98% of the SNPs of 129 and B6 mice are identical, but from 66.6 to 71.9 Mb (including Emilin2), 99% of the SNPs of A/J and 129 mice are identical. In the QTL Hmtb4 on chromosome 5, SNPs in some regions such as 100.3-102.5 Mb (99%) and 105-107.4 Mb (94%), B6 and 129 are similar. On the other hand, A/J and 129 are similar (99%) in the region from 107.6 to 110 Mb, and B6 and A/J are similar (99%) in the region from 103.3 to 104.5 Mb. Because of the complexity feature of this trait, it is hard to hypothesize how the interactions happen, but we do not exclude epistatic interactions among loci. The known functions of other EMILIN proteins, the presence of nonsynonymous SNPs in Emilin2, and expression differences in A/J and B6 from the current study strongly suggest further investigation of Emilin2 as a candidate gene underlying thrombosis susceptibility.
In this study, prolonged clot stability in A/J and B6-Chr17, detected in a bleeding/rebleeding assay, was validated using an assay of direct thrombosis formation and stability. The prolonged clot stability in A/J and B6-Chr17 mice corresponded well to the elevated mRNA expression levels of Emilin2 in A/J and B6-Chr17 mice. These data suggest that the quantitative expression difference of Emilin2 may also be responsible for the phenotypic difference between A/J and B6 mice. In addition, the difference in the clot stability and in the expression of Emilin2 between A/J and B6-Chr17 mice suggests that the causative genes on Chr 17 have epistatic interactions with genes on other chromosomes. These findings are consistent with our previous hypothesis that there were interacting genes on Chrs 5 and 17 (Hoover-Plow et al. 2006; Sa et al. 2008). Our previous studies revealed that the homosomic B6-Chr5 or B6-Chr17 mice had prolonged clot stability as did the A/J parental strain, but the heterosomic mice (B6-Chr5 × B6) F1 or (B6-Chr17 × B6) F1 had values no different than B6 mice. In contrast, the F1 mice from a cross of B6-Chr5 × B6-Chr17 restored the prolonged clot stability to the elevated consomic values (Hoover-Plow et al. 2006). Likewise, other studies (Shavit et al. 2009) have reported several loci that modify the von Willibrand factor that is required for platelet aggregation, and Hasstedt et al. (1998) suggested that there was a modifier gene for protein C that increases thromboembolism risk.
In conclusion, this study identifies nine candidate genes on mouse chromosome 17 for thrombosis susceptibility. Of these candidate genes, Emilin2 is a promising candidate gene that warrants further investigation. Emilin2 is expressed in liver, heart, lung, aorta, and most prominently in bone marrow. Emilin2 is differentially expressed in liver, lung, and bone marrow in B6 and A/J mice. B6 and A/J mice have SNPs in Emilin2 in the coding and regulatory regions. In this study we report that EMILIN2 may function to regulate thrombosis as a component of the vascular wall and is critical for maintaining the vessel architecture in response to injury, and/or as a component of the thrombus-facilitating clot lysis. The identification of novel thrombotic susceptibility genes and their homology in humans may uncover new diagnostic and therapeutic factors of thrombotic risk.
The authors thank Robin Lewis and Subha Raghunathan for assistance with preparation of the manuscript. This study was supported by grants from NIH [HL65204, HL078701 (JHP), and RR12305 (JHN)]. There are no competing financial interests for any of the authors.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.